At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
nilotinibdrug
Likely dose
nilotinib 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of PDGFR Kinase Inhibitor in Biomarker-Enriched Recurrent Malignant Gliomas
In Brief
A Phase 2 clinical trial evaluating nilotinib for Glioma. Completed, enrolled 38 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the survival, disease response, and side effects of Tasigna® (nilotinib) in patients who have malignant gliomas and are positive for Platelet Derived Growth Factor Receptor (PDGFR) amplification. This study is designed to test the hypothesis that patients with malignant gliomas with PDGFR amplification are sensitive to PDGFR kinase inhibitors.
Study Details
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedJun 2010
Primary CompletionOct 2016
Study CompletionJan 2019
TodayJul 2026
First PostedJun 9, 2010
Enrollment StartApr 21, 2010
Primary CompletionOct 5, 2016
Study CompletionJan 1, 2019
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 16.1 years ago
Interventions
nilotinibdrug
400mg po (orally) BID (twice daily)